Pharmaceutical Drugs Is Fastest Growing Segment Fueling The Growth Of Controlled Substance Market

 

Controlled Substance Market

The global Controlled Substance Market is estimated to be valued at US$ 41.8 Bn in 2023 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Controlled substances are pharmaceutical drugs that are regulated by governments and placed under special rules due to potential for abuse or addiction. They are used to treat various conditions like pain, anxiety, depression and insomnia. Controlled substances offer effective treatment options but needs to be used carefully as prescribed to avoid abuse.

Market key trends:
Regulations around prescription and dispensing of controlled substances are getting stricter globally in order to curb the ongoing opioid crisis. Governments are implementing electronic tracking systems to monitor controlled substances from manufacturers to end users. Strict enforcement on overprescription by physicians is being done through prescription drug monitoring programs. Newer controlled substances are being introduced as alternatives to opioids for pain management which are less addictive and have lower abuse potential. Research is also ongoing for developing abuse-deterrent formulations for controlled drugs.


Segment Analysis
The global controlled substance market can be segmented into narcotic drugs, stimulants, depressants, hallucinogens, and anabolic steroids. Among these, narcotic drugs represent the largest and fastest-growing segment, accounting for over 35% of the overall market share in 2023. This is because of their widespread medical application in pain management, especially for opioids like morphine and codeine. Their effectiveness and easy availability have further boosted the sales of narcotic drugs globally.

Key Takeaways
The Global Controlled Substance Market Demand  is expected to witness high growth, exhibiting CAGR of 4.9% over the forecast period, due to increasing prevalence of chronic pain and rise in geriatric population suffering from arthritis, cancer, and other diseases requiring pain management therapies. The market size is projected to reach US$ 41.8 Bn in 2023.

North America accounted for the largest share of over 40% of the global controlled substance market in 2023 due to growing consumption of prescription opioids in pain management and easy availability of these drugs in the region. Asia Pacific is expected to witness the highest CAGR during the forecast period owing to the increasing uptake of medical marijuana and rapid establishment of cannabis dispensaries in emerging countries like China, India, Australia, and South Korea.

Key players operating in the controlled substance market include Johnson & Johnson, Pfizer, Sanofi, Merck & Co., Gilead Sciences, Amgen, Novartis, AbbVie, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva Pharmaceutical, Bayer, Novo Nordisk, Allergan, Takeda Pharmaceutical, Boehringer Ingelheim, Aspen Pharmacare, and Astellas Pharma.

Read More:

https://www.marketwebjournal.com/growing-demand-for-opioid-drugs-to-fuel-the-growth-of-controlled-substance-market/

Comments

Popular posts from this blog

Cellulose Films is the largest segment driving the growth of Cellulose Plastics Market

Electronic Warfare Market Poised to Witness High Growth Owing to Increasing Usage of EW Systems Across Military and Defense Sectors

Poultry Keeping Machinery connected with market drivers for automation